Examkin

Soru

Zorluk: ZorGastroenterology and Hepatology

A 58-year-old man with advanced cirrhosis due to nonalcoholic steatohepatitis is evaluated in the hospital on day 3 of his admission. He originally presented from a skilled nursing facility with fever, worsening ascites, and hepatic encephalopathy. On admission, diagnostic paracentesis revealed cloudy fluid with an absolute neutrophil count of 850/mm³. Due to his recent healthcare exposure and a history of urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing organisms, he was empirically started on intravenous meropenem and received appropriate albumin infusions.

Today, the patient is afebrile, alert, and fully oriented. His abdominal pain has resolved. Blood and ascitic fluid cultures obtained on admission have grown *Escherichia coli*. Antimicrobial susceptibility testing demonstrates that the isolate is resistant to ampicillin but susceptible to ceftriaxone, ciprofloxacin, trimethoprim-sulfamethoxazole, and meropenem.

Which of the following is the most appropriate next step in the pharmacologic management of this patient's infection?

  1. Transition to intravenous ceftriaxoneCevap
  2. B
    Continue intravenous meropenem for a total of 5 to 7 days
  3. C
    Repeat diagnostic paracentesis to ensure decreasing neutrophil count
  4. D
    Transition to oral rifaximin monotherapy
  5. E
    Add intravenous vancomycin

Cevap

The correct management is to transition to intravenous ceftriaxone, de-escalating the antimicrobial therapy based on susceptibility results.
The patient has spontaneous bacterial peritonitis (SBP) and is demonstrating an excellent clinical response to initial empiric therapy. Because he had healthcare exposure and a history of ESBL infections, starting a broad-spectrum agent like meropenem was appropriate. However, once culture results identify a pathogen (E. coli) that is susceptible to narrower-spectrum antibiotics, the standard of care dictates de-escalation. Ceftriaxone is a highly effective, targeted third-generation cephalosporin that serves as the standard first-line treatment for susceptible SBP. Transitioning to ceftriaxone limits unnecessary broad-spectrum exposure while effectively completing the treatment course.

Adım Adım Çözüm

1
Analyze the initial presentation and empiric management.
The patient presented with healthcare-associated spontaneous bacterial peritonitis (SBP) and was appropriately started on broad-spectrum empiric therapy (meropenem) due to a history of ESBL infections.
Empiric coverage must account for the patient's risk factors for resistant organisms.
2
Evaluate the clinical response and microbiological data on day 3.
The patient has clinically improved (afebrile, alert, pain resolved). Cultures grew E. coli susceptible to ceftriaxone, a narrower-spectrum agent.
Clinical improvement confirms the infection is being effectively treated, and susceptibilities guide definitive therapy.
3
Apply principles of antimicrobial stewardship.
Therapy must be de-escalated from meropenem to ceftriaxone.
De-escalation minimizes collateral damage to the microbiome, reduces resistance pressure, and is the standard of care once susceptibility is confirmed.

Anahtar Kavram

Antimicrobial de-escalation in Spontaneous Bacterial Peritonitis (SBP)
Bu soruyu puanla

Konular

Gastroenterology and Hepatology

Bu konudan daha fazla soru